<p><strong>德克萨斯州休斯顿 / ACCESS Newswire /2026 年 3 月 2 日/</strong> Ainos, Inc.（&#34;Ainos&#34;或&#34;公司&#34;）今天发布了董事长、总裁兼首席执行官 Eddy Tsai 致股东的信，概述了在分阶段部署框架下最多可达 20,000 个 AI Nose 系统的经常性收入机会，以及在先进前端半导体制造环境中的持续验证。</p>
<p><strong>致我们的股东，</strong></p>
<p>我很自豪地分享，AI Nose 平台正在从验证阶段的试点转向结构化的工业部署。</p>
<p>确认的首批 1,400 个 AI Nose 系统的订单激活了为期三年的服务结构下的经常性订阅收入，总计约 210 万美元。</p>
<p>这一里程碑标志着我们从概念验证向半导体制造环境中的创收实施的进展。这也反映了我们将 AI Nose 从医疗保健扩展到更广泛工业市场的愿景。</p>
<p>更广泛的路线图考虑在客户设施中分阶段部署最多 20,000 个 AI Nose 系统。如果完全执行，这一框架可能支持接近 1000 万美元的年度订单价值。进入后续阶段仍需根据分阶段的技术验证和与客户的正式合同转换。</p>
<p><strong>平台经济学和经常性收入模型</strong></p>
<p>我们正在将 AI Nose 构建为一个气味智能平台，能够在从医疗保健到工业的广泛行业中扩展。我们的商业架构整合了四个核心组件：</p>
<ul>
<li>边缘硬件部署</li>
<li>基于订阅的分析和监控</li>
<li>持续的 AI 模型优化</li>
<li>跨工业环境的多站点可扩展性</li>
</ul>
<p>这一分层结构旨在支持经常性收入的可见性，同时在部署规模扩大时扩展运营杠杆。随着更多系统上线，预计订阅激活和数据驱动的模型优化将进一步增强平台的长期经济特征。</p>
<p><strong>半导体前端验证</strong></p>
<p>与此同时，AI Nose 正在先进的半导体前端制造设施中进行验证测试——这是世界上技术要求最高的工业环境之一。</p>
<p>这些评估将为在先进晶圆制造设施中的商业整合奠定基础。成功的验证将扩大我们在资本密集型晶圆制造环境中的工业整合机会。</p>
<p>我们将继续专注于有序执行、订阅激活和可扩展基础设施的扩展，致力于将气味定位为下一个 AI 代币——推进气味语言模型（SLM），增强气味 ID 库，并构建由 AI Nose 驱动的 SmellTech，作为工业 AI 系统的基础传感基础设施。</p>
<p>诚挚的，</p>
<p><strong>Eddy Tsai</strong></p>
<p>董事长、总裁兼首席执行官</p>
<p>Ainos, Inc.</p>
<p><strong>关于 AI Nose</strong></p>
<p>AI Nose 将气味数字化为气味 ID，这是一种基于 AI 的气味智能形式。全栈电子鼻平台整合了高精度 MEMS 传感器阵列和专有 AI 算法，旨在支持 ppb 级气味检测灵敏度，具体取决于应用条件和部署配置。气味 ID 将模拟气味信号转换为结构化、可操作的数据，而专有的气味语言模型（SLM）旨在随着时间的推移学习、分类和上下文化复杂的气味模式。</p>
<p>基于十多年积累的气味数据和深厚的医疗技术专业知识，AI Nose 旨在支持工业和制造环境中的持续监测、预测分析和实时警报。AI Nose 以 SmellTech-as-a-Service 架构提供，旨在通过基于订阅的部署模型支持对气味智能、分析和 AI 驱动洞察的持续访问。</p>
<p><strong>关于 Ainos, Inc.</strong></p>
<p>Ainos, Inc.是一家双平台的 AI 和生物技术公司，开创气味技术和免疫治疗。其 AI Nose 平台和气味语言模型（SLM）将气味数字化为气味 ID，这是一种机器可读的数据格式，为机器人、智能工厂和医疗保健提供智能感知。该公司还开发了 VELDONA®，一种针对罕见、自身免疫和传染病的低剂量口服干扰素。Ainos，融合了&#34;AI&#34;和&#34;Nose&#34;，正在重新定义感官时代的机器感知。欲了解更多信息，请访问 https://www.ainos.com。关注 Ainos 在 X（前称 Twitter）上的账号（@AinosInc）和 LinkedIn，以获取最新动态。</p>
<p><strong>前瞻性声明</strong></p>
<p>本信函中的某些陈述属于 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条所定义的前瞻性陈述。除历史事实陈述外的所有陈述均为前瞻性陈述。前瞻性陈述基于管理层对未来事件和趋势的当前假设和预期，这些事件和趋势影响或可能影响公司的业务、战略、运营或财务表现，实际结果和其他事件可能因众多风险和不确定性而与这些陈述中表达或暗示的内容有重大差异。前瞻性陈述本质上受到风险和不确定性的影响，其中一些无法预测或量化。有许多重要因素可能导致实际结果、发展、商业决策或其他事件与本新闻稿中前瞻性陈述所设想的内容有重大差异。这些因素包括但不限于，我们预计在可预见的未来将出现净亏损；我们盈利的能力；我们筹集额外资本以继续产品开发的能力；我们准确预测未来运营结果的能力；我们推进当前或未来产品候选者通过临床试验、获得市场批准并最终商业化我们开发的任何产品候选者的能力；获得和维持我们产品候选者的监管批准的能力；完成当前和未来产品候选者的开发和商业化的延迟；开发和商业化其他产品，包括诊断测试设备；我们在市场上竞争的能力；遵守适用法律、法规和关税的能力，以及在我们向证券交易委员会（SEC）提交的公开文件的风险因素部分中描述的因素。由于前瞻性陈述本质上受到风险和不确定性的影响，因此您不应将这些前瞻性陈述视为未来事件的预测。这些前瞻性陈述仅在本新闻稿发布之日有效，除非适用法律要求，否则公司不承担更新或修订这些陈述的义务，无论是由于任何新信息、未来事件和发展还是其他原因。</p>
<p><strong>联系信息</strong></p>
<p>沈飞飞</p>
<p>ir@ainos.com</p>
<p><strong>来源：</strong> Ainos, Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

标普半导体 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Ainos, Inc. 宣布分阶段部署多达 20,000 套 AI 鼻系统，从验证过渡到工业实施。首批 1,400 套系统的订单将在三年内产生约 210 万美元的经常性收入。该公司旨在将其 AI 鼻平台扩展到各个行业，潜在的年度订单价值接近 1,000 万美元。在半导体制造环境中的持续验证对未来的整合至关重要。Ainos 专注于构建可扩展的嗅觉智能平台，增强其基于订阅的收入模式</p>

<p><strong>HOUSTON, TEXAS / ACCESS Newswire / March 2, 2026 /</strong> Ainos, Inc.  (&#34;Ainos&#34; or the &#34;Company&#34;) today issued the following letter from Chairman, President and Chief Executive Officer Eddy Tsai to shareholders, outlining the recurring revenue opportunity under the phased deployment framework of up to 20,000 AI Nose systems, and ongoing validation within advanced front-end semiconductor fabrication environments.</p>
<div class="lb-trans"><p><strong>德克萨斯州休斯顿 / ACCESS Newswire /2026 年 3 月 2 日/</strong> Ainos, Inc.（&#34;Ainos&#34;或&#34;公司&#34;）今天发布了董事长、总裁兼首席执行官 Eddy Tsai 致股东的信，概述了在分阶段部署框架下最多可达 20,000 个 AI Nose 系统的经常性收入机会，以及在先进前端半导体制造环境中的持续验证。</p>
</div><p><strong>To Our Shareholders,</strong></p>
<div class="lb-trans"><p><strong>致我们的股东，</strong></p>
</div><p>I'm proud to share that the AI Nose platform is transitioning from validation-stage pilots into structured industrial deployment.</p>
<div class="lb-trans"><p>我很自豪地分享，AI Nose 平台正在从验证阶段的试点转向结构化的工业部署。</p>
</div><p>The confirmed initial order of 1,400 AI Nose systems activates recurring subscription revenue under a three-year service structure totaling approximately $2.1 million.</p>
<div class="lb-trans"><p>确认的首批 1,400 个 AI Nose 系统的订单激活了为期三年的服务结构下的经常性订阅收入，总计约 210 万美元。</p>
</div><p>This milestone marks our progression from proof-of-concept validation to revenue-generating implementation within semiconductor manufacturing environments. This also reflects our vision to expand AI Nose from healthcare into the broader industrial market.</p>
<div class="lb-trans"><p>这一里程碑标志着我们从概念验证向半导体制造环境中的创收实施的进展。这也反映了我们将 AI Nose 从医疗保健扩展到更广泛工业市场的愿景。</p>
</div><p>The broader roadmap contemplates phased deployment of up to 20,000 AI Nose systems across customer facilities. If fully executed over time, this framework could support annual order values approaching $10 million. Advancement into subsequent phases remains subject to staged technical validation and formal contractual conversion with our customer.</p>
<div class="lb-trans"><p>更广泛的路线图考虑在客户设施中分阶段部署最多 20,000 个 AI Nose 系统。如果完全执行，这一框架可能支持接近 1000 万美元的年度订单价值。进入后续阶段仍需根据分阶段的技术验证和与客户的正式合同转换。</p>
</div><p><strong>Platform Economics and Recurring Revenue Model</strong></p>
<div class="lb-trans"><p><strong>平台经济学和经常性收入模型</strong></p>
</div><p>We are building AI Nose into a scent intelligence platform, scalable across a broad range of industries, spanning from healthcare to industrials. Our commercial architecture integrates four core components:</p>
<div class="lb-trans"><p>我们正在将 AI Nose 构建为一个气味智能平台，能够在从医疗保健到工业的广泛行业中扩展。我们的商业架构整合了四个核心组件：</p>
</div><ul>
<li>Hardware deployment at the edge</li>
<li>Subscription-based analytics and monitoring</li>
<li>Continuous AI model optimization</li>
<li>Multi-site scalability across industrial environments</li>
</ul>
<div class="lb-trans"><ul>
<li>边缘硬件部署</li>
<li>基于订阅的分析和监控</li>
<li>持续的 AI 模型优化</li>
<li>跨工业环境的多站点可扩展性</li>
</ul>
</div><p>This layered structure aims to support recurring revenue visibility while expanding operating leverage as deployments scale. As additional systems come online, subscription activation and data-driven model refinement are expected to further reinforce the platform's long-term economic profile.</p>
<div class="lb-trans"><p>这一分层结构旨在支持经常性收入的可见性，同时在部署规模扩大时扩展运营杠杆。随着更多系统上线，预计订阅激活和数据驱动的模型优化将进一步增强平台的长期经济特征。</p>
</div><p><strong>Semiconductor Front-End Validation</strong></p>
<div class="lb-trans"><p><strong>半导体前端验证</strong></p>
</div><p>In parallel, AI Nose is undergoing validation testing within advanced semiconductor front-end fabrication facilities - among the most technically demanding industrial environments in the world.</p>
<div class="lb-trans"><p>与此同时，AI Nose 正在先进的半导体前端制造设施中进行验证测试——这是世界上技术要求最高的工业环境之一。</p>
</div><p>These evaluations will set the foundation for commercial integration in advanced wafer fabrication facilities. Successful validation would expand our industrial integration opportunities within capital-intensive wafer fabrication environments.</p>
<div class="lb-trans"><p>这些评估将为在先进晶圆制造设施中的商业整合奠定基础。成功的验证将扩大我们在资本密集型晶圆制造环境中的工业整合机会。</p>
</div><p>We remain focused on disciplined execution, subscription activation, and scalable infrastructure expansion as we position scent as the next AI token - advancing the smell language model (SLM), strengthening Smell ID libraries, and building SmellTech, powered by AI Nose, as a foundational sensing infrastructure for industrial AI systems.</p>
<div class="lb-trans"><p>我们将继续专注于有序执行、订阅激活和可扩展基础设施的扩展，致力于将气味定位为下一个 AI 代币——推进气味语言模型（SLM），增强气味 ID 库，并构建由 AI Nose 驱动的 SmellTech，作为工业 AI 系统的基础传感基础设施。</p>
</div><p>Sincerely,</p>
<div class="lb-trans"><p>诚挚的，</p>
</div><p><strong>Eddy Tsai</strong></p>
<div class="lb-trans"><p><strong>Eddy Tsai</strong></p>
</div><p>Chairman, President &amp; Chief Executive Officer</p>
<div class="lb-trans"><p>董事长、总裁兼首席执行官</p>
</div><p>Ainos, Inc.</p>
<div class="lb-trans"><p>Ainos, Inc.</p>
</div><p><strong>About AI Nose</strong></p>
<div class="lb-trans"><p><strong>关于 AI Nose</strong></p>
</div><p>AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.</p>
<div class="lb-trans"><p>AI Nose 将气味数字化为气味 ID，这是一种基于 AI 的气味智能形式。全栈电子鼻平台整合了高精度 MEMS 传感器阵列和专有 AI 算法，旨在支持 ppb 级气味检测灵敏度，具体取决于应用条件和部署配置。气味 ID 将模拟气味信号转换为结构化、可操作的数据，而专有的气味语言模型（SLM）旨在随着时间的推移学习、分类和上下文化复杂的气味模式。</p>
</div><p>Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.</p>
<div class="lb-trans"><p>基于十多年积累的气味数据和深厚的医疗技术专业知识，AI Nose 旨在支持工业和制造环境中的持续监测、预测分析和实时警报。AI Nose 以 SmellTech-as-a-Service 架构提供，旨在通过基于订阅的部署模型支持对气味智能、分析和 AI 驱动洞察的持续访问。</p>
</div><p><strong>About Ainos, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Ainos, Inc.</strong></p>
</div><p>Ainos, Inc.  is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of &#34;AI&#34; and &#34;Nose,&#34; is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.</p>
<div class="lb-trans"><p>Ainos, Inc.是一家双平台的 AI 和生物技术公司，开创气味技术和免疫治疗。其 AI Nose 平台和气味语言模型（SLM）将气味数字化为气味 ID，这是一种机器可读的数据格式，为机器人、智能工厂和医疗保健提供智能感知。该公司还开发了 VELDONA®，一种针对罕见、自身免疫和传染病的低剂量口服干扰素。Ainos，融合了&#34;AI&#34;和&#34;Nose&#34;，正在重新定义感官时代的机器感知。欲了解更多信息，请访问 https://www.ainos.com。关注 Ainos 在 X（前称 Twitter）上的账号（@AinosInc）和 LinkedIn，以获取最新动态。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this letter are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.</p>
<div class="lb-trans"><p>本信函中的某些陈述属于 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条所定义的前瞻性陈述。除历史事实陈述外的所有陈述均为前瞻性陈述。前瞻性陈述基于管理层对未来事件和趋势的当前假设和预期，这些事件和趋势影响或可能影响公司的业务、战略、运营或财务表现，实际结果和其他事件可能因众多风险和不确定性而与这些陈述中表达或暗示的内容有重大差异。前瞻性陈述本质上受到风险和不确定性的影响，其中一些无法预测或量化。有许多重要因素可能导致实际结果、发展、商业决策或其他事件与本新闻稿中前瞻性陈述所设想的内容有重大差异。这些因素包括但不限于，我们预计在可预见的未来将出现净亏损；我们盈利的能力；我们筹集额外资本以继续产品开发的能力；我们准确预测未来运营结果的能力；我们推进当前或未来产品候选者通过临床试验、获得市场批准并最终商业化我们开发的任何产品候选者的能力；获得和维持我们产品候选者的监管批准的能力；完成当前和未来产品候选者的开发和商业化的延迟；开发和商业化其他产品，包括诊断测试设备；我们在市场上竞争的能力；遵守适用法律、法规和关税的能力，以及在我们向证券交易委员会（SEC）提交的公开文件的风险因素部分中描述的因素。由于前瞻性陈述本质上受到风险和不确定性的影响，因此您不应将这些前瞻性陈述视为未来事件的预测。这些前瞻性陈述仅在本新闻稿发布之日有效，除非适用法律要求，否则公司不承担更新或修订这些陈述的义务，无论是由于任何新信息、未来事件和发展还是其他原因。</p>
</div><p><strong>Contact Information</strong></p>
<div class="lb-trans"><p><strong>联系信息</strong></p>
</div><p>Feifei Shen</p>
<div class="lb-trans"><p>沈飞飞</p>
</div><p>ir@ainos.com</p>
<div class="lb-trans"><p>ir@ainos.com</p>
</div><p><strong>SOURCE:</strong> Ainos, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Ainos, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div>

Ainos Issues Shareholder Letter on Phased AI Nose Deployment of Up to 20,000 Systems and Scalable Recurring Revenue Opportunity

Acceswire

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

Ainos

动态半导体 ETF - Invesco

生物科技 ETF - VanEck Vectors

费城交易所 半导体 ETF - iShares

动态生物技术与基因组 ETF - Invesco

半导体 ETF - VanEck Vectors

Ainos 发布股东信，讨论分阶段部署多达 20,000 个 AI 鼻系统以及可扩展的经常性收入机会